Tag
A post hoc analysis of the CABANA trial reveals that catheter ablation significantly reduces major cardiovascular events and improves quality of life in AF patients with high comorbidity burden (≥4 conditions), suggesting that multimorbidit
A secondary analysis of the PRESTIGE-AF trial reveals that specific MRI markers, including cortical superficial siderosis and macrohemorrhages, are more potent predictors of recurrent intracerebral hemorrhage than hematoma location alone, o
A large-scale registry-based RCT reveals that tailoring atrial fibrillation treatment using the biomarker-driven ABC-AF risk score does not significantly reduce stroke or death compared to current standard guideline-based care, highlighting
The WITHDRAW-AF trial suggests that heart failure therapy can be safely withdrawn in patients with atrial fibrillation-mediated cardiomyopathy who achieve rhythm control and ejection fraction normalization, showing no significant decline in
The STEEER-AF cluster-randomized trial reveals that structured professional education significantly boosts adherence to complex rhythm control guidelines in atrial fibrillation, though it shows no significant impact on stroke prevention whe
A large-scale study of 144,969 Medicare beneficiaries reveals that initial anticoagulant prescriptions for atrial fibrillation may not reduce ischemic stroke risk in patients over 66, while significantly increasing major bleeding hazards, s
A sub-analysis of the Harmony Outcomes trial demonstrates that albiglutide consistently reduces major adverse cardiovascular events in Type 2 diabetes patients, irrespective of baseline atrial fibrillation, while showing a trend toward redu
A longitudinal study reveals that over 5% of patients with MCI or dementia develop new indications for anticoagulants or thrombolytics within a year, complicating the use of anti-amyloid monoclonal antibodies due to increased intracranial h
A landmark study reveals that former world-class rowers face a seven-fold higher risk of atrial fibrillation compared to the general population, driven by a combination of intensive cardiac remodeling and a strong polygenic predisposition.
A large-scale comparative study of 3,508 patients reveals that atrial fibrillation and atherosclerosis produce significantly different vascular brain lesions on MRI, with AF favoring non-lacunar infarcts and periventricular white matter cha
A post hoc analysis of the LOOP study reveals that hypokalaemia is significantly associated with an increased risk of daily atrial fibrillation, particularly longer episodes. The study highlights that deviations from a patient’s indiv
A large-scale cohort study reveals that while rivaroxaban and apixaban offer similar protection against limb events and stroke in patients with AF and PAD, rivaroxaban is associated with a 55% higher risk of major bleeding, suggesting apixa
A large European cohort study reveals that while women with atrial fibrillation are less likely to receive anticoagulants and show higher crude thromboembolism rates, female sex is not an independent risk factor after adjusting for comorbid
A nationwide cohort study demonstrates that NSAID use in patients with atrial fibrillation on oral anticoagulants nearly doubles the risk of hospital-diagnosed bleeding, with significant risks observed across all anticoagulant types and mul
The InsightPFA trial confirms that a novel nanosecond pulsed field ablation (nsPFA) system is noninferior to radiofrequency ablation for paroxysmal atrial fibrillation, significantly reducing procedure and left atrial dwell times while main
The MANIFEST-US study of over 40,000 patients confirms that pulsed field ablation (PFA) for atrial fibrillation maintains a high safety profile in real-world U.S. clinical practice, with a major complication rate of just 0.63% and a complet
This analysis of the EAST-AFNET 4 trial highlights that early rhythm control therapy’s cardiovascular benefits and safety are consistent regardless of diabetes or obesity status in atrial fibrillation patients.
In a randomized trial of 316 patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic disease, adding an antiplatelet to anticoagulation did not reduce ischemic events but doubled clinically relevant bleeding
A UK Biobank whole‑genome study finds polygenic, rare monogenic, and somatic (CHIP) variants each independently associate with incident atrial fibrillation (AF); combined genomic profiling plus clinical risk (CHARGE‑AF) improves discriminat
In patients with overweight/obesity and cardiometabolic comorbidity undergoing first-time AF ablation, a structured, physician‑led program of lifestyle and risk‑factor modification (LRFM) improved freedom from atrial arrhythmia at 12 months
